688656 浩欧博
已收盘 09-11 15:00:00
资讯
新帖
简况
每周股票复盘：浩欧博（688656）上半年净利增37.05%
证券之星 · 03:27
每周股票复盘：浩欧博（688656）上半年净利增37.05%
浩欧博（688656）披露2026年限制性股票激励计划首次授予情况，9月10日股价下跌2.26%
证券之星 · 09-10 22:46
浩欧博（688656）披露2026年限制性股票激励计划首次授予情况，9月10日股价下跌2.26%
浩欧博：9月7日组织现场参观活动，平安证券股份有限公司参与
证券之星 · 09-10
浩欧博：9月7日组织现场参观活动，平安证券股份有限公司参与
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告》
证券之星 · 09-07
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告》
浩欧博(688656.SH)子公司获得13项医疗器械注册证
智通财经 · 09-03
浩欧博(688656.SH)子公司获得13项医疗器械注册证
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年第三次临时股东会会议资料》
证券之星 · 09-03
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年第三次临时股东会会议资料》
浩欧博（688656）披露2026年限制性股票激励计划草案，9月2日股价上涨6.58%
证券之星 · 09-02
浩欧博（688656）披露2026年限制性股票激励计划草案，9月2日股价上涨6.58%
每周股票复盘：浩欧博（688656）推80万股市值激励计划
证券之星 · 08-30
每周股票复盘：浩欧博（688656）推80万股市值激励计划
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票激励计划相关事项的核查意见》
证券之星 · 08-27
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票激励计划相关事项的核查意见》
每周股票复盘：浩欧博（688656）Q2净利同比增56.7%
证券之星 · 08-23
每周股票复盘：浩欧博（688656）Q2净利同比增56.7%
股市必读：浩欧博中报 - 第二季度单季净利润同比增长56.70%
证券之星 · 08-19
股市必读：浩欧博中报 - 第二季度单季净利润同比增长56.70%
浩欧博(688656)6月30日股东户数0.35万户，较上期减少2.31%
证券之星 · 08-18
浩欧博(688656)6月30日股东户数0.35万户，较上期减少2.31%
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年半年度报告摘要》
证券之星 · 08-18
股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年半年度报告摘要》
图解浩欧博中报：第二季度单季净利润同比增长56.70%
证券之星 · 08-18
图解浩欧博中报：第二季度单季净利润同比增长56.70%
浩欧博(688656.SH)发布半年度业绩，归母净利润1667.76万元，同比增长37.05%
智通财经 · 08-17
浩欧博(688656.SH)发布半年度业绩，归母净利润1667.76万元，同比增长37.05%
每周股票复盘：浩欧博（688656）子公司获7项医疗器械注册证
证券之星 · 07-19
每周股票复盘：浩欧博（688656）子公司获7项医疗器械注册证
7月17日浩欧博跌14.24%，嘉实稳福混合A基金重仓该股
证券之星 · 07-17
7月17日浩欧博跌14.24%，嘉实稳福混合A基金重仓该股
浩欧博最新公告：全资子公司获7项医疗器械注册证
证券之星 · 07-15
浩欧博最新公告：全资子公司获7项医疗器械注册证
7月13日浩欧博跌5.33%，嘉实稳福混合A基金重仓该股
证券之星 · 07-13
7月13日浩欧博跌5.33%，嘉实稳福混合A基金重仓该股
7月10日浩欧博涨5.18%，嘉实稳福混合A基金重仓该股
证券之星 · 07-10
7月10日浩欧博涨5.18%，嘉实稳福混合A基金重仓该股
加载更多
公司概况
公司名称：
江苏浩欧博生物医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-13
主营业务：
江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自身免疫性疾病检测。
发行价格：
35.26
{"stockData":{"symbol":"688656","market":"SH","secType":"STK","nameCN":"浩欧博","latestPrice":118.57,"timestamp":1789110000000,"preClose":121.95,"halted":0,"volume":893390,"delay":0,"changeRate":-0.0277,"floatShares":63518600,"shares":63518600,"eps":0.4363,"marketStatus":"已收盘","change":-3.38,"latestTime":"09-11 15:00:00","open":121.96,"high":122.48,"low":114.65,"amount":106000000,"amplitude":0.0642,"askPrice":118.68,"askSize":7,"bidPrice":118.57,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.4363,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":121.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":134.15,"lowLimit":109.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":63518621,"isCdr":false,"pbRate":9.06,"roa":"--","peRate":271.762549,"roe":"2.01%","epsLYR":0.37,"committee":0.519084,"marketValue":7531000000,"turnoverRate":0.0141,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","afterMarket":{"amount":0,"volume":0,"close":118.57,"buyVolume":0,"sellVolume":650,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":121.95},"floatMarketCap":7531000000},"requestUrl":"/m/hq/s/688656","defaultTab":"news","newsList":[{"id":"2667006125","title":"每周股票复盘：浩欧博（688656）上半年净利增37.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667006125","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667006125?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:27","pubTimestamp":1789241229,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，浩欧博报收于118.57元，较上周的104.48元上涨13.49%。本周关注点来自业绩披露要点：2026年上半年公司净利润同比增长37.05%。归属于上市公司股东的净利润为1,667.76万元，同比增长37.05%。剔除股份支付费用减少影响后，净利润同比增长16.16%。出席股东所持表决权占比69.4029%，所有议案均获通过，关联股东已回避表决。所有激励对象获授股票未超过公司总股本1%，全部激励计划累计不超过股本总额20%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594543","title":"浩欧博（688656）披露2026年限制性股票激励计划首次授予情况，9月10日股价下跌2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666594543?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:46","pubTimestamp":1789051576,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，浩欧博报收于121.95元，较前一交易日下跌2.26%，最新总市值为77.46亿元。该股当日开盘128.23元，最高128.23元，最低120.5元，成交额达1.2亿元，换手率为1.54%。近日，江苏浩欧博生物医药股份有限公司披露《董事会薪酬与考核委员会关于公司2026年限制性股票激励计划首次授予激励对象名单的核查意见》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000042629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666635645","title":"浩欧博：9月7日组织现场参观活动，平安证券股份有限公司参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2666635645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666635645?lang=zh_cn&edition=full","pubTime":"2026-09-10 15:18","pubTimestamp":1789024708,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月9日浩欧博发布公告称公司于2026年9月7日组织现场参观活动，平安证券股份有限公司参与。本次推行股权激励，为公司股权激励一贯政策的延续。自2022 年起，公司持续推出第二类限制性股票股权激励计划。截至目前，公司暂无相关投融资及产业并购计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000021601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","161027","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665759362","title":"股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司关于自愿披露全资子公司获得医疗器械注册证的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665759362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665759362?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:11","pubTimestamp":1788714671,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，浩欧博报收于104.48元，下跌0.44%，换手率1.31%，成交量8353.0手，成交额8940.03万元。当日关注点交易信息汇总：9月4日主力资金净流入414.21万元，占总成交额4.63%。公司公告汇总：全资子公司湖南浩欧博获13项医疗器械注册证，覆盖过敏原及自身免疫性疾病相关检测试剂盒，有效期均至2031年8月31日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1583","BK1100","688656","161726","BK0239","BK1574","09996","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987559","title":"浩欧博(688656.SH)子公司获得13项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664987559?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:04","pubTimestamp":1788429879,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)发布公告，公司全资子公司湖南浩欧博生物医药有限公司于近日获得13项由湖南省药品监督管理局核准签发的医疗器械注册证。上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响和促进作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGNG","BK1583","PTH","MDEV","09996","LGHT","IEIH","BK0239","GDOC","688656","HART","159883","MEDX","BK1100","RSPH","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664845677","title":"股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年第三次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664845677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664845677?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:00","pubTimestamp":1788372049,"startTime":"0","endTime":"0","summary":"公司公告汇总：浩欧博拟实施2026年限制性股票激励计划，相关草案及考核管理办法已获第四届董事会第三次会议审议通过。公司公告汇总江苏浩欧博生物医药股份有限公司2026年第三次临时股东会会议资料江苏浩欧博生物医药股份有限公司拟实施2026年限制性股票激励计划，旨在健全公司长效激励机制，吸引和留住优秀人才，调动核心团队积极性，将股东利益、公司利益与核心团队个人利益有机结合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","399441","BK0239","688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810371","title":"浩欧博（688656）披露2026年限制性股票激励计划草案，9月2日股价上涨6.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810371","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810371?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:42","pubTimestamp":1788360135,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，浩欧博报收于107.55元，较前一交易日上涨6.58%，最新总市值为68.31亿元。该股当日开盘102.0元，最高110.2元，最低100.0元，成交额达1.42亿元，换手率为2.1%。近日，江苏浩欧博生物医药股份有限公司披露《2026年限制性股票激励计划（草案）》及其摘要、《2026年限制性股票激励计划实施考核管理办法》，拟实施2026年限制性股票激励计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043573","title":"每周股票复盘：浩欧博（688656）推80万股市值激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663043573?lang=zh_cn&edition=full","pubTime":"2026-08-30 07:21","pubTimestamp":1788045671,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，浩欧博报收于93.69元，较上周的101.78元下跌7.95%。本周关注点公司公告汇总：浩欧博拟推出2026年限制性股票激励计划，拟授予80万股，占总股本1.26%。公司公告汇总江苏浩欧博生物医药股份有限公司董事会薪酬与考核委员会对公司2026年限制性股票激励计划相关事项进行核查，确认公司具备实施股权激励的主体资格，激励对象不包括独立董事、外籍人员及持股5%以上股东及其关联人，符合法规要求，计划未损害公司及股东利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000003830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744489","title":"股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票激励计划相关事项的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744489","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662744489?lang=zh_cn&edition=full","pubTime":"2026-08-27 04:21","pubTimestamp":1787775677,"startTime":"0","endTime":"0","summary":"公司公告汇总江苏浩欧博生物医药股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票激励计划相关事项的核查意见董事会薪酬与考核委员会认为公司具备实施2026年限制性股票激励计划的主体资格，首次授予激励对象不包括独立董事、外籍人员及持股5%以上股东及其关联人，相关安排未侵犯公司及股东利益，不涉及向激励对象提供财务资助。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700009721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239","399441","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214671","title":"每周股票复盘：浩欧博（688656）Q2净利同比增56.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214671","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214671?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:58","pubTimestamp":1787428712,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，浩欧博报收于101.78元，较上周的93.15元上涨9.26%。业绩披露要点浩欧博2026年中报显示，上半年主营收入1.96亿元，同比上升3.22%；归母净利润1667.76万元，同比上升37.05%；扣非净利润1533.08万元，同比上升47.99%。江苏浩欧博生物医药股份有限公司将于2026年8月27日15:00-16:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660159499","title":"股市必读：浩欧博中报 - 第二季度单季净利润同比增长56.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660159499","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660159499?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:29","pubTimestamp":1787074147,"startTime":"0","endTime":"0","summary":"股本股东变化：截至2026年6月30日股东户数为3509.0户，较3月31日减少2.31%，户均持股增至1.81万股。业绩披露要点财务报告2026年中报显示：主营收入1.96亿元，同比上升3.22%；归母净利润1667.76万元，同比上升37.05%；扣非净利润1533.08万元，同比上升47.99%。其中第二季度单季度主营收入1.17亿元，同比上升4.33%；归母净利润1650.01万元，同比上升56.7%；扣非净利润1592.34万元，同比上升57.37%；负债率9.29%，财务费用104.19万元，毛利率60.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660465969","title":"浩欧博(688656)6月30日股东户数0.35万户，较上期减少2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660465969","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660465969?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:27","pubTimestamp":1787045270,"startTime":"0","endTime":"0","summary":"证券之星消息，近日浩欧博披露，截至2026年6月30日公司股东户数为3509.0户，较3月31日减少83.0户，减幅为2.31%。在医疗器械行业个股中，浩欧博股东户数低于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.15万户。从股价来看，2026年3月31日至2026年6月30日，浩欧博区间跌幅为20.27%，在此期间股东户数减少83.0户，减幅为2.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660943163","title":"股市必读：浩欧博新发布《江苏浩欧博生物医药股份有限公司2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660943163","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660943163?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:34","pubTimestamp":1786988088,"startTime":"0","endTime":"0","summary":"公司公告汇总江苏浩欧博生物医药股份有限公司2026年半年度报告摘要截至报告期末，公司总资产为91,643.41万元，归属于上市公司股东的净资产为83,125.23万元。江苏浩欧博生物医药股份有限公司2026年度“提质增效重回报”专项行动方案的半年度评估报告2026年上半年，公司实现营业收入19,576.93万元，同比增长3.22%；归母净利润1,667.76万元，同比增长37.05%，剔除股份支付因素后净利润同比增长16.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0239","688656","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660543909","title":"图解浩欧博中报：第二季度单季净利润同比增长56.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660543909","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660543909?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:13","pubTimestamp":1786986795,"startTime":"0","endTime":"0","summary":"证券之星消息，浩欧博2026年中报显示，上半年度公司主营收入1.96亿元，同比上升3.22%；归母净利润1667.76万元，同比上升37.05%；扣非净利润1533.08万元，同比上升47.99%；其中2026年第二季度，公司单季度主营收入1.17亿元，同比上升4.33%；单季度归母净利润1650.01万元，同比上升56.7%；单季度扣非净利润1592.34万元，同比上升57.37%；负债率9.29%，财务费用104.19万元，毛利率60.34%。财报数据概要请见下图:本文数据来源于浩欧博2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487125","title":"浩欧博(688656.SH)发布半年度业绩，归母净利润1667.76万元，同比增长37.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487125","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660487125?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:20","pubTimestamp":1786969212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浩欧博(688656.SH)披露2026年半年度报告，报告期公司实现营业收入1.96亿元，同比增长3.22%;归属于上市公司股东的净利润1667.76万元，同比增长37.05%;归属于上市公司股东的扣除非经常性损益的净利润1533.08万元，同比增长47.99%;基本每股收益0.27元。公司持续深耕海南自贸港、粤港澳大湾区“药械通”政策落地区域，加大脱敏药欧脱克市场推广投入，带动脱敏药板块收入增长116.83%;诊断检测业务海外市场拓展成效显著，境外销售收入同比提升38.11%;国内诊断业务承压，营业收入微降0.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"浩欧博(688656.SH)发布半年度业绩，归母净利润1667.76万元，同比增长37.05%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230620","title":"每周股票复盘：浩欧博（688656）子公司获7项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230620","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652230620?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:38","pubTimestamp":1784399890,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，浩欧博报收于81.51元，较上周的96.72元下跌15.73%。本周，浩欧博7月16日盘中最高价报99.85元。浩欧博当前最新总市值51.77亿元，在医疗器械板块市值排名62/129，在两市A股市值排名2884/5199。本周关注点公司公告汇总：全资子公司湖南浩欧博获7项医疗器械注册证，涉及多种过敏原检测试剂盒。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","159883","BK1583","BK1100","688656","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652817406","title":"7月17日浩欧博跌14.24%，嘉实稳福混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652817406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652817406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:34","pubTimestamp":1784277261,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日浩欧博跌14.24%创60日新低，收盘报81.51元，换手率1.69%，成交量1.08万手，成交额9320.05万元。嘉实稳福混合A目前规模为1.27亿元，最新净值1.2525，较上一交易日下跌0.38%，近一年上涨2.41%。嘉实稳福混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454578","title":"浩欧博最新公告：全资子公司获7项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454578","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651454578?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:11","pubTimestamp":1784110291,"startTime":"0","endTime":"0","summary":"浩欧博(688656.SH)公告称，公司全资子公司湖南浩欧博生物医药有限公司近日获得7项由湖南省药品监督管理局核准签发的医疗器械注册证，包括过敏原特异性IgE抗体检测试剂盒(坚果混合FX28、霉菌混合MX14、树木混合TX1、海鲜混合FX3、水果混合FX30、草混合WX1)及热带无爪螨过敏原特异性IgE抗体测定试剂盒。上述产品均采用磁微粒化学发光法，用于过敏症的辅助诊断。此次获证丰富了公司化学发光平台检测菜单，有助于提升市场竞争力，但实际销售情况取决于未来市场拓展效果。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500037349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK0239","BK1583","BK1574","688656","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651019474","title":"7月13日浩欧博跌5.33%，嘉实稳福混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651019474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651019474?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:36","pubTimestamp":1783931775,"startTime":"0","endTime":"0","summary":"证券之星消息，7月13日浩欧博跌5.33%，收盘报91.56元，换手率0.93%，成交量5878.0手，成交额5474.69万元。重仓浩欧博的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为嘉实基金的嘉实稳福混合A。嘉实稳福混合A目前规模为1.27亿元，最新净值1.2625，较上一交易日下跌0.17%，近一年上涨3.3%。嘉实稳福混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688656","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183941","title":"7月10日浩欧博涨5.18%，嘉实稳福混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650183941?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:26","pubTimestamp":1783671993,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日浩欧博涨5.18%创60日新低，收盘报96.72元，换手率1.13%，成交量7151.0手，成交额6896.73万元。重仓浩欧博的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为嘉实基金的嘉实稳福混合A。嘉实稳福混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000028963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688656"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789291032860,"stockEarnings":[{"period":"1week","weight":0.1349},{"period":"1month","weight":0.2748},{"period":"3month","weight":0.2099},{"period":"6month","weight":-0.1395},{"period":"1year","weight":-0.1892},{"period":"ytd","weight":-0.2277}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏浩欧博生物医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"3509人(较上一季度减少2.31%)","perCapita":"18101股","listingDate":"2021-01-13","address":"江苏省苏州市虎丘区中国(江苏)自由贸易试验区苏州片区苏州工业园区东堰里路9号","registeredCapital":"6351万元","survey":" 江苏浩欧博生物医药股份有限公司的主营业务是体外诊断试剂的研发、生产和销售。公司的主要产品是IgE检测、食物特异性IgG检测、自身免疫性疾病检测。","listedPrice":35.26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浩欧博,688656,浩欧博股票,浩欧博股票老虎,浩欧博股票老虎国际,浩欧博行情,浩欧博股票行情,浩欧博股价,浩欧博股市,浩欧博股票价格,浩欧博股票交易,浩欧博股票购买,浩欧博股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浩欧博(688656)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浩欧博(688656)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}